Placebo + Seralutinib
Phase 3Active 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Hypertension Associated With Interstitial Lung Disease
Conditions
Pulmonary Hypertension Associated With Interstitial Lung Disease
Trial Timeline
Feb 1, 2026 → Dec 1, 2028
NCT ID
NCT07181382About Placebo + Seralutinib
Placebo + Seralutinib is a phase 3 stage product being developed by Gossamer Bio for Pulmonary Hypertension Associated With Interstitial Lung Disease. The current trial status is active. This product is registered under clinical trial identifier NCT07181382. Target conditions include Pulmonary Hypertension Associated With Interstitial Lung Disease.
What happened to similar drugs?
20 of 20 similar drugs in Pulmonary Hypertension Associated With Interstitial Lung Disease were approved
Approved (20) Terminated (1) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07181382 | Phase 3 | Active |
| NCT05934526 | Phase 3 | Completed |
Competing Products
20 competing products in Pulmonary Hypertension Associated With Interstitial Lung Disease